Tumor Types

Friday, July 4, 2025

Infections in CAR- T

 

 

Prophylaxis Post CAR-T infections

Prophylaxis     Preferred Drugs       Alternate          Start     End

1.       Antibacterial (with Pseudomonas coverage)           

a.       Preferred: Fluoroquinolones (Levofloxacin 500mg PO daily)

b.       Alternate: Cefpodoxime 200mg PO BID      

c.       Start with: Onset of neutropenia (ANC < 500/mm3)           

d.       Stop when: Recovery of neutropenia (ANC > 500/mm3)

2.       Antiviral (for HSV/VZV prevention)   

a.       Preferred Acyclovir 400-800mg PO BID       

b.       Alternate: Valacyclovir 500mg PO daily, Famciclovir 250mg PO BID              

c.       Start with lymphodepletion  Continue until CD4 counts > 200 or at least 6 months

3.       Antifungals     

a.       Preferred Fluconazole 200mg PO daily (standard risk).  Posaconazole 300mg PO daily          

b.       Alternate: Micafungin 50 IV q24H (if LFT abnormality)       

c.       Start with Onset of neutropenia (ANC < 500/mm3)            

d.       Stop when: Recovery of neutropenia (ANC > 500/mm3)

4.       Antifungals in high risk * (high risk= mold coverage for patients with prior fungal infection, and/or high dose corticosteroids)

a.       Voriconazole 200mg PO two times a day, Posaconazole 300mg PO daily

b.       Start of high dose steroids, other risk factors          

c.       Mold prophylaxis for 1 month after completion of Immune suppressive therapies

5.       Anti-PJP pneumonia

a.       Trimethoprim/Sulfamethoxazole 1 double-strength PO three times a week.

b.       Alternate: pentamidine 300 mg monthly inhaled. Dapsone 100 mg PO daily. Atovaquone 1500 mg PO daily     

c.       Start: Day 28 

d.       Stop: Continue at least 3 months, until CD4 > 200/uL

6.       Hepatitis B carriers/exposed ( HBs Ag positive or Anti-HBc Ab IgG positive)

a.       Entecavir                                       

b.       Start At least 6 months and surveillance of LFT and HBV DNA as indicated.


at July 04, 2025
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

Primary CNS lymphoma

 Reference: Annals of Oncology  June 2024 ESMO guidelines Diagnosis  Recommendations • Contrast-enhanced cranial MRI is the recommended imag...

  • FLT 3 mutation and inhibitors in AML
    Type 1 inhibitors good against TKD and ITD FLT3 ( ITD is the one associated with shorter DOR and higher relapse rates) Type 2 ( quizartinib ...
  • Ovarian ca PARP flowchart
      Frontline is platinum based chemo with or without bev.   G ermline BRCA or HRD, negative - - Observation is ok, Niraparib cat 2A based on ...
  • Relapsed refractory DLBCL
      1. Tafasitamab - CD 19 Ab:  approved with lenalidomide for patients with R/R DLBCL ineligible for ASCT. median OS 3 yr. 2L, ineligible for...
  • Home

Search This Blog

Blog Archive

  • ▼  2025 (35)
    • ►  November (8)
    • ►  September (2)
    • ►  August (3)
    • ▼  July (2)
      • AML
      • Infections in CAR- T
    • ►  June (2)
    • ►  May (3)
    • ►  April (4)
    • ►  March (2)
    • ►  February (4)
    • ►  January (5)
  • ►  2024 (51)
    • ►  December (14)
    • ►  November (8)
    • ►  October (4)
    • ►  September (10)
    • ►  August (3)
    • ►  July (5)
    • ►  May (3)
    • ►  April (3)
    • ►  March (1)
  • ►  2023 (43)
    • ►  December (1)
    • ►  November (3)
    • ►  October (6)
    • ►  September (5)
    • ►  August (5)
    • ►  July (7)
    • ►  June (2)
    • ►  May (4)
    • ►  April (3)
    • ►  March (2)
    • ►  January (5)
  • ►  2022 (19)
    • ►  October (4)
    • ►  September (5)
    • ►  August (5)
    • ►  July (1)
    • ►  June (3)
    • ►  April (1)
  • ►  2021 (28)
    • ►  December (1)
    • ►  October (1)
    • ►  September (2)
    • ►  May (5)
    • ►  April (6)
    • ►  March (2)
    • ►  February (6)
    • ►  January (5)
  • ►  2020 (2)
    • ►  December (1)
    • ►  October (1)

Report Abuse

Simple theme. Powered by Blogger.